Literature DB >> 1287032

Targeted kill: from umbrellas to monoclonal antibodies.

V S Byers1, R W Baldwin.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1287032     DOI： 10.1007/bf00918851

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  53 in total

1.  Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action.

Authors:  V S Byers; I Z Pawluczyk; D S Hooi; M R Price; S Carroll; M J Embleton; M C Garnett; N Berry; R A Robins; R W Baldwin
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

2.  A phase I/II study of trichosanthin treatment of HIV disease.

Authors:  V S Byers; A S Levin; L A Waites; B A Starrett; R A Mayer; J A Clegg; M R Price; R A Robins; M Delaney; R W Baldwin
Journal:  AIDS       Date:  1990-12       Impact factor: 4.177

3.  Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenografts.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

4.  Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice.

Authors:  A Pacheco-Silva; M G Bastos; R A Muggia; O Pankewycz; J Nichols; J R Murphy; T B Strom; V E Rubin-Kelley
Journal:  Eur J Immunol       Date:  1992-03       Impact factor: 5.532

5.  Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins.

Authors:  M J Bjorn; D Ring; A Frankel
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

6.  Human immune response to multiple injections of murine monoclonal IgG.

Authors:  D L Shawler; R M Bartholomew; L M Smith; R O Dillman
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

7.  Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma.

Authors:  C F LeMaistre; S Rosen; A Frankel; S Kornfeld; E Saria; C Meneghetti; J Drajesk; D Fishwild; P Scannon; V Byers
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

8.  New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Authors:  P E Thorpe; P M Wallace; P P Knowles; M G Relf; A N Brown; G J Watson; R E Knyba; E J Wawrzynczak; D C Blakey
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

9.  Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model.

Authors:  M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 12.779

10.  Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice.

Authors:  J W Pearson; D J FitzGerald; M C Willingham; R H Wiltrout; I Pastan; D L Longo
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 13.312
View more
  3 in total

1.  Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.

Authors:  V S Byers; E B Austin; J A Clegg; G Denton; B Gunn; D Hooi; F Hudecz; M R Price; R W Baldwin
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

2.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

3.  Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.

Authors:  B H Woo; J T Lee; K C Lee
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.